IntelliCyt Corporation

Genetic Engineering and Biotechnology News | April 24, 2020

Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently in EMBO Molecular Medicine through an article entitled “Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody”—s...

Research

Maxcyte, Inc. | August 12, 2021

MaxCyte, Inc., a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines. Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitle...

MedTech

Medtronic plc | October 01, 2021

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ ...

Northwest Biotherapeutics | August 12, 2020

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...